-
US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties
•
Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to influence discourse surrounding China’s biotech sector. This week, Gallagher, along with Republican Raja Krishnamoorthi, sent a letter to US Defense Secretary Lloyd Austin, inquiring about updates on a Pentagon security review of several Chinese biotechnology…
-
Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results
•
Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its financial report for 2023, showcasing a significant increase in revenues to RMB 225 million (USD 31 million), marking a year-on-year (YOY) growth of 1,347%. This substantial revenue included RMB 124 million (USD 17.1 million) from…
-
Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production
•
Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen Pharmaceutical have entered into a comprehensive agreement with Swiss pharmaceutical giant Novartis. The agreement covers technology transfer, manufacturing, and clinical supply services for the co-developed therapy Carvykti (ciltacabtagene autoleucel; cilta-cel). As per the terms, Novartis…
-
Danaher Corporation Partners with Chongqing Liang Jiang New Area to Establish Western Innovation Center
•
Danaher Corporation (NYSE: DHR), a leading science and technology services provider in the U.S., has entered into a partnership with the Chongqing Liang Jiang New Area government to establish the Danaher Western Innovation Center in the district. This new center, located adjacent to the Children’s Hospital of Chongqing Medical University,…
-
China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases
•
China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement with US-based Incyte Pharmaceuticals Inc. (NSDQ: INCY), focusing on Incyte’s selective oral JAK1 inhibitor, povorcitinib. CMS has secured the exclusive rights to research, develop, file for regulatory approval, and commercialize the drug in Greater China,…
-
Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced the commencement of two Phase III clinical studies in collaboration with Japan’s Meiji Seika Pharma. These studies are focused on their co-developed anti-infective, Nacubactam (OP0595), which is being tested in combination…
-
Johnson & Johnson MedTech Launches CPX4 PLUS Tissue Expander for Breast Reconstruction in China
•
Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading healthcare conglomerate in the US, has announced the official market launch of its CPX4 PLUS tissue expander in China. This marks the introduction of the first breast tissue-specific expander in the country, designed to benefit a greater number of breast cancer…
-
ETERN Therapeutics Secures Funding to Advance LLPS Platform and Clinical Trials for Anti-Tumor Drugs
•
ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a Series B+ financing round. The initial phase of this funding round was co-led by the AZ-CICC Fund and another Wuxi-based fund, with participation from Wuxi Capital. The capital raised will be directed towards the construction…
